This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.

Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


7er2

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (17:00, 29 November 2023) (edit) (undo)
 
Line 1: Line 1:
==Crystal structure of EGFR 696-1022 T790M/C797S in complex with LS_2_40==
==Crystal structure of EGFR 696-1022 T790M/C797S in complex with LS_2_40==
-
<StructureSection load='7er2' size='340' side='right'caption='[[7er2]]' scene=''>
+
<StructureSection load='7er2' size='340' side='right'caption='[[7er2]], [[Resolution|resolution]] 2.66&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
-
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7ER2 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7ER2 FirstGlance]. <br>
+
<table><tr><td colspan='2'>[[7er2]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=7ER2 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=7ER2 FirstGlance]. <br>
-
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7er2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7er2 OCA], [https://pdbe.org/7er2 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7er2 RCSB], [https://www.ebi.ac.uk/pdbsum/7er2 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7er2 ProSAT]</span></td></tr>
+
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.662&#8491;</td></tr>
 +
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=JAU:5-chloranyl-N2-[3-chloranyl-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-N4-(2-dimethylphosphorylphenyl)pyrimidine-2,4-diamine'>JAU</scene></td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=7er2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=7er2 OCA], [https://pdbe.org/7er2 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=7er2 RCSB], [https://www.ebi.ac.uk/pdbsum/7er2 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=7er2 ProSAT]</span></td></tr>
</table>
</table>
 +
== Disease ==
 +
[https://www.uniprot.org/uniprot/EGFR_HUMAN EGFR_HUMAN] Defects in EGFR are associated with lung cancer (LNCR) [MIM:[https://omim.org/entry/211980 211980]. LNCR is a common malignancy affecting tissues of the lung. The most common form of lung cancer is non-small cell lung cancer (NSCLC) that can be divided into 3 major histologic subtypes: squamous cell carcinoma, adenocarcinoma, and large cell lung cancer. NSCLC is often diagnosed at an advanced stage and has a poor prognosis.
 +
== Function ==
 +
[https://www.uniprot.org/uniprot/EGFR_HUMAN EGFR_HUMAN] Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin.<ref>PMID:7657591</ref> <ref>PMID:11602604</ref> <ref>PMID:12873986</ref> <ref>PMID:10805725</ref> <ref>PMID:11116146</ref> <ref>PMID:11483589</ref> <ref>PMID:17115032</ref> <ref>PMID:21258366</ref> <ref>PMID:12297050</ref> <ref>PMID:12620237</ref> <ref>PMID:15374980</ref> <ref>PMID:19560417</ref> <ref>PMID:20837704</ref> Isoform 2 may act as an antagonist of EGF action.<ref>PMID:7657591</ref> <ref>PMID:11602604</ref> <ref>PMID:12873986</ref> <ref>PMID:10805725</ref> <ref>PMID:11116146</ref> <ref>PMID:11483589</ref> <ref>PMID:17115032</ref> <ref>PMID:21258366</ref> <ref>PMID:12297050</ref> <ref>PMID:12620237</ref> <ref>PMID:15374980</ref> <ref>PMID:19560417</ref> <ref>PMID:20837704</ref>
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
A series of brigatinib derivatives were designed and synthesized as new potent and selective EGFR(T790M/C797S) inhibitors. One of the most potent and selective compounds 18k strongly suppressed the EGFR(L858R/T790M/C797S) and EGFR(19Del/T790M/C797S) kinases with IC50 values of 0.7 and 3.6 nM, respectively, which were over 54-fold more potent than the lead compound. 18k also demonstrated promising EGFR(T790M/C797S) mutant selectivity, and was 94-fold less potent against the wild type EGFR. A cocrystal structure of EGFR(T790M/C797S) with a close derivative 18f was solved to provide insight on the inhibitor's binding mode. Moreover, compound 18k was orally bioavailable and demonstrated highly desirable PK properties, making it a promising lead compound for further structural optimization.
 +
 +
Optimization of Brigatinib as New Wild-Type Sparing Inhibitors of EGFR(T790M/C797S) Mutants.,Li S, Zhang T, Zhu SJ, Lei C, Lai M, Peng L, Tong L, Pang Z, Lu X, Ding J, Ren X, Yun CH, Xie H, Ding K ACS Med Chem Lett. 2022 Jan 7;13(2):196-202. doi: 10.1021/acsmedchemlett.1c00555., eCollection 2022 Feb 10. PMID:35178175<ref>PMID:35178175</ref>
 +
 +
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
 +
</div>
 +
<div class="pdbe-citations 7er2" style="background-color:#fffaf0;"></div>
 +
 +
==See Also==
 +
*[[Epidermal growth factor receptor 3D structures|Epidermal growth factor receptor 3D structures]]
 +
== References ==
 +
<references/>
__TOC__
__TOC__
</StructureSection>
</StructureSection>
 +
[[Category: Homo sapiens]]
[[Category: Large Structures]]
[[Category: Large Structures]]
[[Category: Yun CH]]
[[Category: Yun CH]]
[[Category: Zhu SJ]]
[[Category: Zhu SJ]]

Current revision

Crystal structure of EGFR 696-1022 T790M/C797S in complex with LS_2_40

PDB ID 7er2

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "http://52.214.119.220/wiki/index.php/7er2"
Personal tools